

The purpose of the study is to find out whether a dietary intervention can affect treatment response and/or quality of life for people with newly diagnosed multiple myeloma receiving standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd). The researchers will measure quality of life by having participants complete questionnaires. The study will investigate the effects of diet on quality of life, treatment response, and other disease, microbiome, and immune markers.





Enter contact info
We need your contact info for the study team to get in touch with you
Create an alert
Would you like us to notify you if new site gets added near your preferred location?
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
We have recorded your responses successfully. You will be notified when a new site matching your preferred location is added to the system.
We have recorded your responses successfully. You will not be notified when a new site matching your preferred location is added to the system.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Your information has been sent successfully. A study member will get in touch with you soon.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
The prescreener preview is complete. You may now close the preview.
